Lipid and glucose alterations in HIV-infected children beginning or changing antiretroviral therapy

Pediatrics

Volumn 122, Issue 1, 2008, Pages

  Chantry, Caroline J ^a   Hughes, Michael D ^b   Alvero, Carmelita ^b   Cervia, Joseph S ^c   Meyer III, William A ^d   Hodge, Janice ^e   Borum, Peggy ^f   Moye Jr , Jack ^g  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

^e FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^f UNIVERSITY OF FLORIDA   (United States)

^g EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

Apolipoprotein; Children; Cholesterol; Glucose; HIV; Immune reconstitution; Insulin; Insulin like growth factor binding protein; Insulin like growth factor 1; Insulin resistance; Triglycerides; Viral load

Indexed keywords

APOLIPOPROTEIN; CD4 ANTIGEN; GLUCOSE; GROWTH FACTOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; VIRUS RNA; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADOLESCENT; ARTICLE; CENTERS FOR DISEASE CONTROL AND PREVENTION; CHILD; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL INTAKE; CLINICAL EVALUATION; DISEASE CONTROL; ETHNICITY; FEMALE; GENDER; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; INSULIN BLOOD LEVEL; LIPID BLOOD LEVEL; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY; NUTRITIONAL ASSESSMENT; PRIORITY JOURNAL; PROPHYLAXIS; RACE; SCORING SYSTEM; VIRUS LOAD; BLOOD; HOMEOSTASIS; INSULIN RESISTANCE; MULTIVARIATE ANALYSIS; NEWBORN; NUTRITION; PRESCHOOL CHILD;

ADOLESCENT; BLOOD GLUCOSE; CHILD; CHILD, PRESCHOOL; CHOLESTEROL, LDL; FEMALE; HIV INFECTIONS; HOMEOSTASIS; HUMANS; INFANT; INFANT, NEWBORN; INSULIN RESISTANCE; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 1; INSULIN-LIKE GROWTH FACTOR I; LIPIDS; LIPOPROTEINS, HDL; MALE; MULTIVARIATE ANALYSIS; NUTRITION SURVEYS; TRIGLYCERIDES;

EID: 48249129695     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2007-2467     Document Type: Article

References (37)

1. El-Sadr WM, Mullln CM, Carr A, et al. Effects of HIV disease on lipid, glucose and insulin levels: results from a large antiretroviral-naive cohort. HIV Med. 2005;6(2):114-121
2. Mulligan K, Grunfeld C, Tai VW, Algren H, Pang M, Chernoff DN. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr. 2000; 23(1):35-43
3. Kosmiski LA, Kuritzkes DR, Lichtenstein KA, et al. Fat distribution and metabolic changes are strongly correlated and energy expenditure is increased in the HIV lipodystrophy syndrome. AIDS. 2001;15(15):1993-2000
4. Beregszaszi M, Dollfus C, Levine M, et al. Longitudinal evaluation and risk factors of lipodystrophy and associated metabolic changes in HIV-infected children. J Acquir Immune Defic Syndr. 2005;40(2):161-168
5. Sánchez Torres AM, Munoz Muniz R, Madero R, Borque C, García-Miguel M, Isabel De José Gómez M. Prevalence of fat redistribution and metabolic disorders in human immunodeficiency virus-infected children. Eur J Pediatr. 2005;164(5): 271-276
6. Guimarães MM, de Oliveira AR Jr, Penido MG, et al. Ultra-sonographic measurement of intra-abdominal fat thickness in HIV-infected patients treated or not with antiretroviral drugs and its correlation to lipid and glycemic profiles. Ann Nutr Metab. 2007;51(1):35-41
7. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Coop DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet. 1999; 353(9170):2093-2099
8. Carter RJ, Wiener J, Abrams EJ, et al. Dyslipidemia among perinatally HIV-infected children enrolled in the PACTS-HOPE cohort, 1999-2004: a longitudinal analysis. J Acquir Immune Defic Syndr. 2006;41(4):453-460
9. Lapphra K, Vanprapar N, Phongsamart W, Chearskul P, Chokephaibulkit K. Dyslipidemia and lipodystrophy in HIV- infected Thai children on highly active antiretroviral therapy (HAART). J Med Assoc Thai. 2005;88(7):956-966
10. d'Arminio A, Sabin CA, Phillips AN, et al. Cardio- and cerebrovascular events in HIV-infected persons. AIDS. 2004;18(13):1811-1817
11. Lorenz MW, Stephan C, Harmjanz A, et al. Both long-term HIV infection and highly active antiretroviral therapy are independent risk factors for early carotid atherosclerosis. Atherosclerosis. 2008;196(2):720-726
12. Falutz J, Allas S, Kotler D, et al. A placebo-controlled, doseranging study of a growth hormone releasing factor in HIV- infected patients with abdominal fat accumulation. AIDS. 2005;19(12):1279-1287
13. Solórzano Santos F, Gochicoa Rangel LG, Palacios Saucedo G, Vazquez Rosales G, Miranda Novales MG. Hypertriglyceridemia and hypercholesterolemia in human immunodeficiency virus-1-infected children treated with protease inhibitors. Arch Med Res. 2006;37(1):129-132
14. Amaya RA, Kozinetz CA, McMeans A, Schwarzwald H, Kline MW. Lipodystrophy syndrome in human immunodeficiency virus-infected children. Pediatr Infect Dis J. 2002;21(5):405-410
15. Viganò A, Mora S, Brambilla P, Schneider L, Merlo M, Monti LD, Manzoni P. Impaired growth hormone secretion correlates with visceral adiposity in highly active antiretroviral treated HIV-infected adolescents. AIDS. 2003;17(10):1435-1441
16. Farley J, Gona P, Crain M, et al. Prevalence of elevated cholesterol and associated risk factors among perinatally HIV- infected children (4-19 years old) in Pediatric AIDS Clinical Trials Group 219C. Acquir Immune Defic Syndr. 2005;38(4): 480-487
17. Jaquet D, Lévine M, Ortega-Rodriguez E, et al. Clinical and metabolic presentation of the lipodystrophic syndrome in HIV- infected children. AIDS. 2000;14(14):2123-2128
18. Wallace TM, Levy JC, Matthews, DR. Use and abuse of HOMA modeling. Diabetes Care. 2004;27(6):1487-1495
19. Centers for Disease Control and Prevention. National Center for Health Statistics. National Health and Nutrition Examination Survey. Hyattsville, MD: US Department of Health and Human Services. Available at: www.cdc.gov/nchs/nhanes/htm. Accessed May 16, 2007
20. Bachorik PS, Lovejoy KL, Carroll MD, Johnson CL. Apolipoprotein B and AI distributions in the United States, 1988 -1991: results of the National Health and Nutrition Examination Survey III (NHANES III). Clin Chem. 1997;43(12):2364-2378
21. Gunn VL, Nechyba C, eds. The Harriet Lane Handbook: A Manual for Pediatric Houseofficers. 16th ed. Philadelphia, PA, Mosby;2002
22. Fisher DA, ed. Pediatric Endocrinology. San Juan Capistrano, CA: Quest Diagnostics; 2000
23. Tresaco B, Bueno G, Pineda I, Moreno LA, Garagorri JM, Bueno M. Homeostatic model assessment (HOMA) index cutoff values to identify the metabolic syndrome in children. J Physiol Biochem. 2005;61(2):381-388
24. Centers for Disease Control and Prevention. 1994 revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR Recomm Rep. 1994;43(RR-12):1-10
25. Lichtenstein AH, Appel LJ, Brands M, et al. Diet and lifestyle recommendations revision 2006: a scientific statement from the American Heart Association Nutrition Committee. Circulation. 2006;114(1):82-96
26. Rhoads MP, Smith CJ, Tudor-Williams G, et al. Effects of highly active antiretroviral therapy on paediatric metabolite levels. HIV Med. 2006;7(1):16-24
27. Floris-Moore M, Howard AA, Lo Y, Arnsten JH, Santoro N, Schoenbaum EE. Increased serum lipids are associated with higher CD4 lymphocyte count in HIV-infected women. HIV Med. 2006;7(7):421-430
28. Rose H, Woolley I, Hoy J, et al. HIV infection and high-density lipoprotein: the effect of the disease vs the effect of treatment. Metabolism. 2006;55(1):90-95
29. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998;12(7):F51-F58
30. Ergun-Longmire B, Lin-Su K, Dunn AM, et al. Effects of protease inhibitors on glucose tolerance, lipid metabolism, and body composition in children and adolescents infected with human immunodeficiency virus. Endocr Pract. 2006;12(5):514-521
31. Bitnun A, Sochett E, Babyn P, et al. Serum lipids, glucose homeostasis and abdominal adipose tissue distribution in protease inhibitor-treated and naive HIV-infected children. AIDS. 2003;17(9):1319-1324
32. Shlay JC, Bartsch G, Peng G, et al. Long-term body composition and metabolic changes in antiretroviral naive persons randomized to protease inhibitor-, nonnucleoside reverse transcriptase inhibitor-, or protease inhibitor plus nonnucleoside reverse transcriptase inhibitor-based strategy. J Acquir Immune Defic Syndr. 2007;44(5):506-517
33. Mujawar Z, Rose H, Morrow MP, et al. Human immunodeficiency virus impairs reverse cholesterol transport form macrophages. PLoS Biol. 2006;4(11):e365
34. Chantry C, Hughes M, Alvero C, et al. Growth and body composition in children beginning or changing ART [abstract MOAB0403]. Proceedings of the XVI International AIDS Conference; August 13-18, 2006; Toronto, Ontario, Canada
35. Chantry CJ, Hughes MD, Alvero C, et al. Insulin-like growth factor-1 and lean body mass in HIV-infected children. J Acquir Immune Defic Syndr. 2008; In press
36. D'Amico S, Shi J, Sekhar RV, et al. Physiologic growth hormone replacement improves fasting lipid kinetics in patients with HIV lipodystrophy syndrome. Am J Clin Nutr. 2006;84(1): 204-211
37. Rondanelli M, Caselli D, Arico M, Maccabruni A, Magnani B, Bacchella L. Insulin-like growth factor I (IGF-I) and IGF- binding protein 3 response to growth hormone is impaired in HIV-infected children. AIDS Res Hum Retroviruses. 2002;18(5): 331-339